Top

Current Breast Cancer Reports

Published in:

01-06-2019 | Breast Cancer | Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)

Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer

Authors: Carolyn Hall, Vanessa Sarli, Salyna Meas, Anthony Lucci

Published in: Current Breast Cancer Reports | Issue 2/2019

Abstract

Purpose of Review

Liquid biopsies are easily obtainable, non-invasive, longitudinal snapshots that can be used to measure micrometastatic disease burden, monitor disease progression, and provide genomic assessments of primary tumor/metastatic lesions. To date, most published studies have focused on circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA); however, the liquid biopsy field is expanding exponentially and new blood components are currently under investigation.

Recent Findings

CTCs and ctDNA remain the most extensively studied liquid biopsy components to date. Several additional blood-based components are the basis of active, ongoing investigations. Some on the horizon include serum/plasma exosomes, platelet-mRNA, miRNA characterization, and global proteomic studies.

Summary

In the era of individualized medicine, liquid biopsy has potential to improve upon current breast cancer management by offering dynamic monitoring possibilities as well as novel targets for therapy.

Nelson NJ. Circulating tumor cells: will they be clinically useful? J Natl Cancer Inst. 2010;102(3):146–8. https://doi.org/10.1093/jnci/djq016.CrossRefPubMed

Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623–31. https://doi.org/10.1038/nrc3820.CrossRefPubMed

Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol. 2016;10(3):374–94. https://doi.org/10.1016/j.molonc.2016.01.007.CrossRefPubMedPubMedCentral

Lee JS, Magbanua MJM, Park JW. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat. 2016;160(3):411–24. https://doi.org/10.1007/s10549-016-4014-6.CrossRefPubMed

Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res. 2011;31(3):979–84.PubMed

Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14 Pt 1):4218–24.CrossRefPubMed

Martín M, Custodio S, Maestro De Las Casas ML, García-Sáenz JA, De La Torre JC, Bellón-Cano JM, et al. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer. Oncologist. 2013;18(8):917–23. https://doi.org/10.1634/theoncologist.2012-0479.CrossRefPubMedPubMedCentral

Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 2010;17(3):199–204. https://doi.org/10.1007/s12282-009-0139-3.CrossRefPubMed

Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406–14. https://doi.org/10.1016/s1470-2045(14)70069-5.CrossRefPubMed

10.

Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010;116(14):3330–7.CrossRefPubMed

11.

Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2010;21(4):729–33. https://doi.org/10.1093/annonc/mdp391.CrossRefPubMed

12.

•• Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018;110(6):560–7. https://doi.org/10.1093/jnci/djy018A large, pooled analysis study demonstrating the prognostic significance of CTcs in the neoadjuvant setting. CrossRefPubMed

13.

Franken B, de Groot MR, Mastboom WJ, Vermes I, van der Palen J, Tibbe AG, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14(5):R133. https://doi.org/10.1186/bcr3333.CrossRefPubMedPubMedCentral

14.

Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res. 2016;22(10):2583–93. https://doi.org/10.1158/1078-0432.CCR-15-1603.CrossRefPubMed

15.

Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13(7):688–95. https://doi.org/10.1016/S1470-2045(12)70209-7.CrossRefPubMed

16.

Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Instit. 2014;106(5). https://doi.org/10.1093/jnci/dju066.

17.

van Dalum G, van der Stam GJ, Tibbe AG, Franken B, Mastboom WJ, Vermes I, et al. Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol. 2015;46(1):407–13. https://doi.org/10.3892/ijo.2014.2694.CrossRefPubMed

18.

Hall CS, Karhade MG, Bowman Bauldry JB, Valad LM, Kuerer HM, DeSnyder SM, et al. Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J Am Coll Surg. 2016;223(1):20–9. https://doi.org/10.1016/j.jamcollsurg.2016.02.021.CrossRefPubMedPubMedCentral

19.

Riethdorf S, Muller V, Loibl S, Nekljudova V, Weber K, Huober J, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res. 2017;23(18):5384–93. https://doi.org/10.1158/1078-0432.CCR-17-0255.CrossRefPubMed

20.

Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S et al. Circulating tumor cells and recurrence after primary systemic therapy in stage III inflammatory breast cancer. J Natl Cancer Inst. 2015;107(11). https://doi.org/10.1093/jnci/djv250.CrossRefPubMedPubMedCentral

21.

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, et al. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol. 2017;28(1):103–9. https://doi.org/10.1093/annonc/mdw535.CrossRefPubMed

22.

Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, et al. Efficacy of lapatinib in therapy-resistant HER2-positive circulating tumor cells in metastatic breast cancer. PLoS One. 2015;10(6):e0123683. https://doi.org/10.1371/journal.pone.0123683.CrossRefPubMedPubMedCentral

23.

Stebbing J, Payne R, Reise J, Frampton AE, Avery M, Woodley L, et al. The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS One. 2013;8(5):e62543. https://doi.org/10.1371/journal.pone.0062543.CrossRefPubMedPubMedCentral

24.

Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulias V. Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Cancer Chemother Pharmacol. 2014;73(4):685–93. https://doi.org/10.1007/s00280-014-2387-y.CrossRefPubMed

25.

Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat. 2012;134(1):283–9. https://doi.org/10.1007/s10549-012-2045-1.CrossRefPubMed

26.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol. 2012;23(7):1744–50. https://doi.org/10.1093/annonc/mds020.CrossRefPubMed

27.

Hainsworth JD, Murphy PB, Alemar JR, Daniel BR, Young RR, Yardley DA. Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy. Breast Cancer Res Treat. 2016;160(1):41–9. https://doi.org/10.1007/s10549-016-3969-7.CrossRefPubMed

28.

Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehm T, et al. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, treat CTC): a randomized phase II trial. Ann Oncol. 2018;29(8):1777–83. https://doi.org/10.1093/annonc/mdy211.CrossRefPubMed

29.

Jaeger BA, Albrecht S, Schochter F, Melcher CA, Hagenbeck C, Friedl TW, et al. Abstract OT1-2-03: the DETECT-study concept: treatment based on the phenotype of circulating tumor cells in HER2-negative metastatic breast cancer. Cancer Res. 2015;75(9 Supplement):OT1-2-03-OT1-2. https://doi.org/10.1158/1538-7445.sabcs14-ot1-2-03.CrossRef

30.

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32(31):3483–9. https://doi.org/10.1200/JCO.2014.56.2561.CrossRefPubMedPubMedCentral

31.

Helissey C, Berger F, Cottu P, Dieras V, Mignot L, Servois V, et al. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. Cancer Lett. 2015;360(2):213–8. https://doi.org/10.1016/j.canlet.2015.02.010.CrossRefPubMed

32.

Bidard FC, Pierga JY. Clinical utility of circulating tumor cells in metastatic breast cancer. J Clin Oncol. 2015;33(14):1622. https://doi.org/10.1200/jco.2014.57.9714.CrossRefPubMed

33.

Arslan C, Sari E, Aksoy S, Altundag K. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets. 2011;15(1):21–30. https://doi.org/10.1517/14656566.2011.537260.CrossRefPubMed

34.

Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11(4):R46.CrossRefPubMedPubMedCentral

35.

Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, Villarin E, et al. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol. 2015;17(7):539–46. https://doi.org/10.1007/s12094-015-1275-1.CrossRefPubMedPubMedCentral

36.

Paoletti C, Muniz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res. 2015;21(11):2487–98. https://doi.org/10.1158/1078-0432.ccr-14-1913.CrossRefPubMed

37.

Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011;128(1):155–63. https://doi.org/10.1007/s10549-011-1508-0.CrossRefPubMedPubMedCentral

38.

Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2009;115(3):581–90.CrossRefPubMed

39.

Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403–12. https://doi.org/10.1007/s10549-010-1163-x.CrossRefPubMed

40.

Krishnamurthy S, Bischoff F, Ann Mayer J, Wong K, Pham T, Kuerer H, et al. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med. 2013;2(2):226–33. https://doi.org/10.1002/cam4.70.CrossRefPubMedPubMedCentral

41.

Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer. 2010;10(5):392–7. https://doi.org/10.3816/CBC.2010.n.052.CrossRefPubMed

42.

Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16(9):2634–45.CrossRefPubMed

43.

Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodriguez M, Garcia-Puche JL, et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012;14(3):R71. https://doi.org/10.1186/bcr3180.CrossRefPubMedPubMedCentral

44.

Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer. 2010;102(10):1495–502.CrossRefPubMedPubMedCentral

45.

Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, et al. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol. 2012;17(2):96–104. https://doi.org/10.1007/s10147-011-0260-0.CrossRefPubMed

46.

Mayer JA, Pham T, Wong KL, Scoggin J, Sales EV, Clarin T, et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE platform. Cancer Genet. 2011;204(11):589–95. https://doi.org/10.1016/j.cancergen.2011.10.011.CrossRefPubMed

47.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34. https://doi.org/10.1200/JCO.2005.04.7985.CrossRefPubMed

48.

Pizon M, Zimon DS, Pachmann U, Pachmann K. Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients. PLoS One. 2013;8(2):e56836. https://doi.org/10.1371/journal.pone.0056836.CrossRefPubMedPubMedCentral

49.

de Kruijff IE, Sieuwerts AM, Onstenk W, Jager A, Hamberg P, de Jongh FE, et al. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. Int J Cancer. 2019. https://doi.org/10.1002/ijc.32209.CrossRefPubMed

50.

Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015;9(4):749–57. https://doi.org/10.1016/j.molonc.2014.12.001.CrossRefPubMed

51.

Mu Z, Benali-Furet N, Uzan G, Znaty A, Ye Z, Paolillo C et al. Detection and characterization of circulating tumor associated cells in metastatic breast cancer. Int J Mol Sci. 2016;17(10). https://doi.org/10.3390/ijms17101665.CrossRefPubMedCentral

52.

Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res. 2017;23(1):88–96. https://doi.org/10.1158/1078-0432.Ccr-16-0825.CrossRefPubMed

53.

Paolillo C, Mu Z, Rossi G, Schiewer MJ, Nguyen T, Austin L, et al. Detection of activating estrogen receptor gene (<em>ESR1</em>) mutations in single circulating tumor cells. Clin Cancer Res. 2017;23(20):6086–93. https://doi.org/10.1158/1078-0432.ccr-17-1173.CrossRefPubMedPubMedCentral

54.

Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, et al. Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Res. 2018;78(4):1110–22. https://doi.org/10.1158/0008-5472.Can-17-2686.CrossRefPubMed

55.

Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: a comprehensive review. Clin Genet. 2019. https://doi.org/10.1111/cge.13514.CrossRefPubMed

56.

Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, et al. Circulating tumor DNA analysis in breast cancer: is it ready for prime-time? Cancer Treat Rev. 2019;73:73–83. https://doi.org/10.1016/j.ctrv.2019.01.004.CrossRefPubMed

57.

Schwarzenbach H, Pantel K. Circulating DNA as biomarker in breast cancer. Breast Cancer Res. 2015;17(1):136. https://doi.org/10.1186/s13058-015-0645-5.CrossRefPubMedPubMedCentral

58.

Wang R, Li X, Zhang H, Wang K, He J. Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker. Oncotarget. 2017;8(43):75742–55. https://doi.org/10.18632/oncotarget.20608.CrossRefPubMedPubMedCentral

59.

Marzese DM, Hirose H, Hoon DS. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn. 2013;13(8):827–44. https://doi.org/10.1586/14737159.2013.845088.CrossRefPubMed

60.

El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222–30. https://doi.org/10.1016/j.cca.2013.05.022.CrossRefPubMed

61.

Zeerleder S. The struggle to detect circulating DNA. Crit Care. 2006;10(3):142. https://doi.org/10.1186/cc4932.CrossRefPubMedPubMedCentral

62.

Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014;20(10):2643–50. https://doi.org/10.1158/1078-0432.CCR-13-2933.CrossRefPubMedPubMedCentral

63.

Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010;120(2):461–7. https://doi.org/10.1007/s10549-010-0747-9.CrossRefPubMed

64.

Agassi R, Czeiger D, Shaked G, Avriel A, Sheynin J, Lavrenkov K, et al. Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. Am J Clin Pathol. 2015;143(1):18–24. https://doi.org/10.1309/AJCPI5YHG0OGFAHM.CrossRefPubMed

65.

Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 2006;243(1):64–70. https://doi.org/10.1016/j.canlet.2005.11.027.CrossRefPubMed

66.

Tangvarasittichai O, Jaiwang W, Tangvarasittichai S. The plasma DNA concentration as a potential breast cancer screening marker. Indian J Clin Biochem. 2015;30(1):55–8. https://doi.org/10.1007/s12291-013-0407-z.CrossRefPubMed

67.

Catarino R, Ferreira MM, Rodrigues H, Coelho A, Nogal A, Sousa A, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 2008;27(8):415–21. https://doi.org/10.1089/dna.2008.0744.CrossRefPubMed

68.

Magbanua MB-SL, Hirst G, Yau C, Wolf D, Ma A, et al. Editor. Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL. San Antonio: SABCS; 2018.

69.

Sotiriou C, Rothe F, Maetens M, Fumagalli D, Brown DN, Salgado R et al. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III trial. Cancer Res. 2018;78(4).

70.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133. https://doi.org/10.1126/scitranslmed.aab0021.CrossRefPubMed

71.

Riva F, Bidard F-C, Houy A, Saliou A, Madic J, Rampanou A, et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem. 2017;63(3):691–9. https://doi.org/10.1373/clinchem.2016.262337.CrossRefPubMed

72.

Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, et al. Association of Cell-Free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast Cancer. J Clin Oncol. 2018;36(6):543–53. https://doi.org/10.1200/JCO.2017.76.0033.CrossRefPubMedPubMedCentral

73.

Takahashi H, Kagara N, Tanei T, Naoi Y, Shimoda M, Shimomura A, et al. Correlation of methylated circulating tumor DNA with response to neoadjuvant chemotherapy in breast cancer patients. Clin Breast Cancer. 2017;17(1):61. https://doi.org/10.1016/j.clbc.2016.06.006.CrossRefPubMed

74.

Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005;65(4):1141–5. https://doi.org/10.1158/0008-5472.CAN-04-2438.CrossRefPubMed

75.

Fujita N, Nakayama T, Yamamoto N, Kim SJ, Shimazu K, Shimomura A, et al. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology. 2012;83(5):273–82. https://doi.org/10.1159/000342083.CrossRefPubMed

76.

Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, et al. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 2010;87(3–4):83–91. https://doi.org/10.1016/j.lfs.2010.05.001.CrossRefPubMed

77.

Oshiro C, Kagara N, Naoi Y, Shimoda M, Shimomura A, Maruyama N, et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat. 2015;150(2):299–307. https://doi.org/10.1007/s10549-015-3322-6.CrossRefPubMed

78.

Chen YH, Hancock BA, Solzak JP, Brinza D, Scafe C, Miller KD, et al. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer. 2017;3:24. https://doi.org/10.1038/s41523-017-0028-4.CrossRefPubMedPubMedCentral

79.

Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2(10):1310–5. https://doi.org/10.1001/jamaoncol.2016.1279.CrossRefPubMedPubMedCentral

80.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961–8. https://doi.org/10.1200/JCO.2016.67.3061.CrossRefPubMed

81.

Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O'Leary B, Kilburn L, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol. 2018;29(1):145–53. https://doi.org/10.1093/annonc/mdx483.CrossRefPubMed

82.

• O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018;9(1):896. https://doi.org/10.1038/s41467-018-03215-xDemonstrated the predictive importance of serial ctDNA measurements during therapy. CrossRefPubMedPubMedCentral

83.

Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C, et al. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget. 2016;7(46):74448–59. https://doi.org/10.18632/oncotarget.12950.CrossRefPubMedPubMedCentral

84.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7(313):313ra182. https://doi.org/10.1126/scitranslmed.aac7551.CrossRefPubMedPubMedCentral

85.

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016;7:11579. https://doi.org/10.1038/ncomms11579.CrossRefPubMedPubMedCentral

86.

Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904–16. https://doi.org/10.1016/S1470-2045(17)30376-5.CrossRefPubMedPubMedCentral

87.

Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2-advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017;116(6):726–30. https://doi.org/10.1038/bjc.2017.25.CrossRefPubMedPubMedCentral

88.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7. https://doi.org/10.1093/annonc/mdy155.CrossRefPubMed

89.

Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, Muller-Holzner E, et al. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat. 2011;130(1):109–17. https://doi.org/10.1007/s10549-010-1335-8.CrossRefPubMed

90.

Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–209. https://doi.org/10.1056/NEJMoa1213261.CrossRefPubMed

91.

Rossi G, Mu Z, Rademaker AW, Austin LK, Strickland KS, Costa RLB, et al. Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res. 2018;24(3):560–8. https://doi.org/10.1158/1078-0432.CCR-17-2092.CrossRefPubMed

92.

•• Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, et al. Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD phase I trial. Clin Cancer Res. 2018;24(23):5860–72. https://doi.org/10.1158/1078-0432.Ccr-18-1569Combined both CTC and ctDNA information to assess pharmacodynamics and early efficacy of the anti-estrogen therapy. CrossRefPubMed

93.

•• Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–30. https://doi.org/10.1126/science.aar3247First study to combine proteomics and ctDNA for early cancer detection. CrossRefPubMedPubMedCentral

Title: Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer
Authors: Carolyn Hall
Vanessa Sarli
Salyna Meas
Anthony Lucci
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Trastuzumab
Fulvestrant
Exemestane
Published in: Current Breast Cancer Reports / Issue 2/2019
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-019-0308-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2019

Surgical Therapy for Women with Multiple Synchronous Ipsilateral Breast Cancer (MIBC): Current Evidence to Guide Clinical Practice

Ablative Treatment of Breast Cancer; Are We There Yet?

Practical Perspectives Regarding Patient Selection and Technical Considerations in Oncoplastic Surgery

Correction to: Ablative Treatment of Breast Cancer; Are We There Yet?

Interval Cancers and Duty of Candour, a UK Perspective

Diffusion-Weighted Magnetic Resonance Imaging of the Breast: an Accurate Method for Measuring Early Response to Neoadjuvant Chemotherapy?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer